Economic Drivers and Trade-Offs in Antibody Purification Processes - The future of therapeutic MAbs lies in the development of economically feasible downstream processes. - BioPharm International

ADVERTISEMENT

Economic Drivers and Trade-Offs in Antibody Purification Processes
The future of therapeutic MAbs lies in the development of economically feasible downstream processes.


BioPharm International Supplements


25. Aldington S, Bonnerjea J. Scale-up of monoclonal antibody purification processes. J Chromatogr B. 2007;848:64–78.

26. Zhou J, Tressel T. Basic concepts in Q membrane chromatography for large-scale antibody production. Biotechnol Progr. 2006;22:341-349.

27. Warner WM, Nochumson S. Rethinking the economics of chromatography. BioPharm Int. 2003 Jan; 58–60.

28. Jagschies G, O'Hara A. Debunking downstream bottleneck myth. Gen Eng News. 2007 Aug;27(14).

29. Thiel KA. Biomanufacturing, from bust to boom... to bubble? Nat Biotechnol. 2004;22:1365–1372.

30. Smith M. An evaluation of Protein A and non-Protein A methods for the recovery of monoclonal antibodies and considerations for process scale-up. Proceedings of scaling-up of biopharmaceutical products. 2004 Jan 26–27; Amsterdam.

31. Sofer G, Chirica LC. Improving productivity in downstream processing, Pharm Tech Eur. 2007 Apr.

32. Davies J, Smith, M, Bonnerjea J. The influence of scale of operation on purification process design. Proceedings of 154th Society for General Microbiology Meeting, 2004 29 March–2 April, Bath, UK.

33. Thömmes J, Etzel M. Alternatives to chromatographic separations. Biotechnol Progr. 2007;23(1):42–45.

34. Knudsen H, Fahrner R, Xu Y, Norling L, Blank G. Membrane ion-exchange chromatography for process-scale antibody purification. J Chromatogr A. 2001;907:145–154.

35. Boi C. Membrane adsorbers as purification tools for monoclonal antibody purification. J Chromatogr B. 2007;848:19–27.

36. Lim JAC, Sinclair A, Kim DS, Gottschalk U. Economic benefits of single use membrane chromatography in polishing: A cost of goods model. BioProcess Int. 2007;5(2):60–64.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

New Tax Rules May Deter Future Pharma M&A
October 1, 2014
NIH Seeks to Improve Vaccine Response with New Adjuvants
September 30, 2014
New Report Details Players and Pipelines in the Biosimilar Space
September 30, 2014
Baxter International Plans to Open R&D Center for Baxalta
September 30, 2014
FDA Releases First-Ever Purple Book for Biosimilar Characterization
September 26, 2014
Author Guidelines
Source: BioPharm International Supplements,
Click here